Type 1 Diabetes: Advances in Understanding and Treatment 100 Years After the Discovery of Insulin, Second Edition

Click to Enlarge				Type 1 Diabetes: Advances in Understanding and Treatment 100 Years After the Discovery of Insulin, Second Edition Subject Area(s): Human Biology and Disease; Biochemistry; Biophysics Edited by Jeffrey A. Bluestone, Sonoma Biotherapeutics; Kevan C. Herold, Yale School of Medicine; Lori Sussel, University of Colorado Anschutz Medical Center *Download a Free Excerpt from Type 1 Diabetes: Advances in Understanding and Treatment 100 Years After the Discovery of Insulin, Second Edition:* Preface The Pathogenesis of Type 1 Diabetes Index

				© 2025 • 370 pages, illustrated (49 color and 1 B&W), index Hardcover • $79 ISBN 978-1-621825-07-4

Description Contents Description Type 1 diabetes, sometimes called juvenile-onset or insulin-dependent diabetes, is an autoimmune condition in which the β cells in the pancreas that produce insulin are destroyed by the body’s immune system. The disease affects millions of individuals, but for more than 100 years, diet and insulin injections were the only effective treatment. Recent discoveries, however, have led to new therapies and finally the promise of a cure. Written and edited by experts in the field, this new collection from Cold Spring Harbor Perspectives in Medicine discusses exciting research that has increased our understanding of the mechanisms underlying development of type 1 diabetes. The contributors discuss immunological, genetic and environmental contributions to disease susceptibility, the part β cells play, and how interactions with the immune system drive pathogenesis. They examine the failure of immune tolerance, the role of T cells, specific features of autoimmunity, and the importance of neoantigens in the disease, as well as the important question of whether it is β cells or the immune system that becomes dysfunctional first. In addition, the volume reviews the incredible progress in development of treatments for type 1 diabetes, including novel therapies that rebalance the immune system and pancreatic islet-cell transplantation. The long journey to approval of teplizumab to treat individuals at high risk is also covered. The new book will therefore be of interest to all endocrinologists and immunologists seeking to learn more about this disease but also those working in drug development. Contents Preface The Pathogenesis of Type 1 Diabetes Kevan C. Herold and Jeffrey P. Krischer Environmental Factors in Type 1 Diabetes Heikki Hyöty, Jutta E. Laiho, and Suvi M. Virtanen Breakdown and Repair of Peripheral Immune Tolerance in Type 1 Diabetes Gerald T. Nepom Monogenic Type 1 Diabetes: A High Yield Pool in Which to Discover New Mechanisms and Candidate Therapeutics for Type 1 Diabetes Chester E. Chamberlain, Michael S. German, Louis H. Philipson, and Mark S. Anderson Advancing Animal Models of Human Type 1 Diabetes David V. Serreze, Jennifer R. Dwyer, and Jeremy J. Racine Cross Talk between β Cells and Immune Cells: What We Know, What We Think We Know, and What We Should Learn Fatoumata Samassa, Capucine Holtzmann, and Roberto Mallone Inflammatory β-Cell Stress and Immune Surveillance in Type 1 Diabetes Anil Bhushan and Peter J. Thompson The Chicken or the Egg Dilemma: Understanding the Interplay between the Immune System and the β Cell in Type 1 Diabetes Maria Skjøtt Hansen, Pravil Pokharel, Jon Piganelli, and Lori Sussel The Human Pancreas in Type 1 Diabetes: Lessons Learned from the Network of Pancreatic Organ Donors with Diabetes Irina Kusmartseva, Amanda Posgai, Mingder Yang, Richard Oram, Mark Atkinson, Alberto Pugliese, and Carmella Evans-Molina The Role of B Lymphocytes in Type 1 Diabetes Mia J. Smith, Joanne Boldison, and F. Susan Wong Innate Immunity in Type 1 Diabetes Léo Bertrand, Alexander V. Chervonsky, and Agnès Lehuen T Cell Differentiation in Autoimmune Type 1 Diabetes Andrea Schietinger, Ian T. McBain, Katrina M. Hawley, and Svetlana Miakicheva Genetics and Epigenetics of Type 1 Diabetes Self-Reactive T Cells Tae Gun Kang and Benjamin Youngblood Epitope Hierarchy in Type 1 Diabetes Pathogenesis Thomas Delong and Maki Nakayama Integrating Omics into Functional Biomarkers of Type 1 Diabetes S. Alice Long and Peter S. Linsley Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease Zoe Quandt, Ana Perdigoto, Mark S. Anderson, and Kevan C. Herold Rebalancing the Immune System to Treat Type 1 Diabetes Yannick D. Muller, Patrick Ho, Jeffrey A. Bluestone, and Qizhi Tang Clinical Immunologic Interventions for the Treatment of Type 1 Diabetes: Challenges, Choice, and Timing of Immunomodulators Danijela Tatovic and Colin Dayan Autoantigen-Specific Immunotherapies for the Prevention and Treatment of Type 1 Diabetes Mark Peakman and Pere Santamaria The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation Lucienne Chatenoud, Kevan C. Herold, Jean-François Bach, and Jeffrey A. Bluestone Advances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes Timothy J. Kieffer, Corinne A. Hoesli, and A.M. James Shapiro Index

Type 1 Diabetes: Advances in Understanding and Treatment 100 Years After the Discovery of Insulin, Second Edition

Description

Contents